Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

被引：0
|
作者：
Dong, Wei [1 ]
Zhang, Songyan [1 ]
Huo, Zhuoni [1 ]
Lu, Junrong [1 ]
Liu, Haishi [1 ]
Wang, Ping [1 ]
Zhang, Yubao [1 ]
机构：
[1] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16160
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy(HAIC) Combined with PD-1 Inhibitors for Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Multicenter Propensity Score Matching Analysis
    Zhang, Fengtao
    Zhong, Sheng
    Wei, Qiming
    Zhang, Haiming
    Hu, Honglei
    Zeng, Bicheng
    Zheng, Xiang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1961 - 1978
  • [22] Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and PD-1 Inhibitors for Managing Arterioportal Shunt in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Cohort Study
    Liu, Guanxiong
    Zhu, Duo
    He, Quansheng
    Zhou, Churen
    He, Li
    Li, Zhengran
    Jiang, Zaibo
    Huang, Mingsheng
    Chang, Boyang
    Wu, Chun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1415 - 1428
  • [23] The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review
    Yuanren, Gao
    Yin, Linan
    Liu, Ruibao
    Cui, Yali
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium
    Lou, Yidan
    Zhang, Xiaoling
    Sun, Pengfei
    Chang, Xu
    ACADEMIC RADIOLOGY, 2025, 32 (02) : 787 - 797
  • [25] Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.
    Yin, Linan
    Liu, Ruibao
    Li, Shijie
    Hou, Xunbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
    Wu, Yintao
    Zhu, Jianyong
    Zhang, Hong
    Xia, Nianxin
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 239 - 247
  • [27] Hepatic Arterial Infusion Chemotherapy (HAIC) with Interferon Is Very Useful for Unresectable Hepatocellular Carcinoma (HCC)
    Kirikoshi, Hiroyuki
    Saito, Satoru
    Yoneda, Masato
    Fujita, Koji
    Mawatari, Hironori
    Lida, Hiroshi
    Uchiyama, Takashi
    Nozaki, Yuichi
    Takahashi, Hirokazu
    Abe, Yasunobu
    Inamori, Masahiko
    Kobayashi, Noritoshi
    Kubota, Kensuke
    Nakajima, Atsushi
    GASTROENTEROLOGY, 2009, 136 (05) : A861 - A861
  • [28] Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
    He, Min-Ke
    Liang, Run-Bin
    Zhao, Yang
    Xu, Yu-Jie
    Chen, Huan-Wei
    Zhou, Yuan-Min
    Lai, Zhi-Cheng
    Xu, Li
    Wei, Wei
    Zhang, Yao-Jun
    Chen, Min-Shan
    Guo, Rong-Ping
    Li, Qi-Jiong
    Shi, Ming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] NEOADJUVANT CADONILIMAB ( PD-1/ CTLA-4 BISPECIFIC ANTIBODY) PLUS TRANSHEPATIC ARTERIAL INFUSION CHEMOTHERAPY ( HAIC) WITH FOLFOX FOR RESECTABLE MULTINODULAR CNLC Ib/ IIa HEPATOCELLULAR CARCINOMA
    Wei, Yonguang
    Zeng, Zhiming
    Zhu, Guangzhi
    Lv, Zili
    Peng, Tao
    HEPATOLOGY, 2023, 78 : S1861 - S1862
  • [30] Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
    Ni, Jia-yan
    Sun, Hong-liang
    Guo, Ge-fan
    Zhou, Xiong
    Wei, Jin-xing
    Xu, Lin-feng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 140
12345